<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04577781</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG3970-CL-209</org_study_id>
    <secondary_id>2020-000658-83</secondary_id>
    <nct_id>NCT04577781</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate</brief_title>
  <acronym>LADYBUG</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of GLPG3970, Administered Orally for 6 Weeks in Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the effect of GLPG3970 compared to placebo&#xD;
      on the signs and symptoms of Rheumatoid Arthritis (RA) in participants with moderately to&#xD;
      severely active RA and an inadequate response to methotrexate (MTX).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2020</start_date>
  <completion_date type="Actual">April 7, 2021</completion_date>
  <primary_completion_date type="Actual">March 26, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Disease Activity Score Based on 28 Joints (DAS28) (C-reactive protein [CRP]) at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-emergent Adverse Events (TEAEs) by Severity</measure>
    <time_frame>Screening up to Follow-up (Week 11)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Plasma Trough Concentration (Ctrough) of GLPG3970</measure>
    <time_frame>Predose (within 30 minutes prior to dosing) on Days 15, 29 and 43</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>GLPG3970</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GLPG3970 solution, orally, once daily for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo solution, orally, once daily for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3970</intervention_name>
    <description>GLPG3970 powder and solvent for oral solution to be reconstituted prior to use.</description>
    <arm_group_label>GLPG3970</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo powder and solvent for oral solution to be reconstituted prior to use.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. A body mass index (BMI) between 18-32 kg/m^2, inclusive.&#xD;
&#xD;
          2. Diagnosis of RA ≥6 months prior to screening AND meeting the 2010 American College of&#xD;
             Rheumatology (ACR)/ European League Against Rheumatism (EULAR) criteria of RA AND ACR&#xD;
             functional class I-III.&#xD;
&#xD;
          3. Have ≥6 swollen joints (from a swollen joint count evaluated in 66 joints [SJC66]) AND&#xD;
             ≥8 tender joints (from a tender joint count evaluated in 68 joints [TJC68]) at&#xD;
             screening and at the baseline visit (Visit 1) prior to the first investigational&#xD;
             product (IP) dosing.&#xD;
&#xD;
          4. DAS28 (CRP) &gt;3.2 (moderate disease) at screening.&#xD;
&#xD;
          5. Screening serum hsCRP &gt; upper limit of normal (ULN, central laboratory reference: ≤&#xD;
             5.0 mg/L).&#xD;
&#xD;
          6. Inadequate response to MTX, i.e. treatment-experienced participants who demonstrated&#xD;
             inadequate clinical response during treatment with MTX.&#xD;
&#xD;
          7. Have received MTX for ≥6 months and on stable dose (10 to 20 mg/week) of MTX for at&#xD;
             least 4 weeks prior to screening and willing to continue on their current stable dose&#xD;
             and dosing regimen for the duration of the study.&#xD;
&#xD;
          8. If taking systemic steroids, prednisone equivalent at a dose of ≤10 mg/day and stable&#xD;
             for at least 4 weeks prior to the first IP dosing.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Current therapy with any conventional disease-modifying antirheumatic drug (DMARD)&#xD;
             other than MTX, including&#xD;
&#xD;
               1. oral or injectable gold, sulfasalazine, antimalarials, azathioprine, or&#xD;
                  D-penicillamine within 4 weeks prior to screening,&#xD;
&#xD;
               2. cyclosporine within 8 weeks prior to screening, and&#xD;
&#xD;
               3. leflunomide within 3 months prior to screening or a minimum 4 weeks prior to&#xD;
                  screening if after 11 days of standard cholestyramine therapy.&#xD;
&#xD;
          2. Current or previous treatment with a biologic DMARD (bDMARD). Except for participants&#xD;
             who received bDMARDs only in a single clinical study setting:&#xD;
&#xD;
               1. For whom the last dose of bDMARD ≥6 months prior to screening (12 months for&#xD;
                  rituximab or other lymphocyte depleting agents), AND;&#xD;
&#xD;
               2. For whom the bDMARD was effective, without being discontinued due to lack of&#xD;
                  efficacy.&#xD;
&#xD;
          3. Participants who received an intra-articular or parenteral corticosteroid injection&#xD;
             within 4 weeks prior to screening.&#xD;
&#xD;
          4. Participants who received a prior surgical intervention within 12 weeks prior to&#xD;
             screening or likely requirement for surgery during the study.&#xD;
&#xD;
          5. Participant has a history of tuberculosis (TB) diagnosis or evidence of active or&#xD;
             latent infection with Mycobacterium tuberculosis as defined by one of the following&#xD;
             assessments:&#xD;
&#xD;
               1. Positive QuantiFERON-TB Gold test result at screening, OR&#xD;
&#xD;
               2. Chest radiograph (posterior anterior view) taken within 12 weeks prior to&#xD;
                  screening, read by a qualified radiologist or pulmonologist, with evidence of&#xD;
                  current active TB or old inactive TB.&#xD;
&#xD;
          6. Participant has any active systemic infection within the last 2 weeks prior to first&#xD;
             IP dosing, or poorly controlled chronic cardiac, pulmonary or renal disease.&#xD;
&#xD;
          7. Participant has a known or suspected history of or a current immunosuppressive&#xD;
             condition, or a history of invasive opportunistic infections (e.g. human&#xD;
             immunodeficiency virus [HIV] infection, histoplasmosis, listeriosis, coccidiodmycosis,&#xD;
             pneumocystosis, aspergillosis).&#xD;
&#xD;
          8. Participant has a chronic hepatitis B virus (HBV) infection, as defined by persistent&#xD;
             HBV surface antigen (HBsAg) positivity. Participant has hepatitis C virus (HCV)&#xD;
             infection, as defined by positive HCV antibody at screening and detectable HCV&#xD;
             viremia. Participants with positive HCV antibody must undergo reflex HCV ribonucleic&#xD;
             acid (RNA) testing, and participants with HCV RNA positivity will be excluded.&#xD;
             Participants with positive HCV antibody and negative HCV RNA are eligible.&#xD;
&#xD;
          9. Participant testing positive at screening for severe acute respiratory syndrome&#xD;
             coronavirus 2 (SARS-CoV-2) infection as detected by real time polymerase chain&#xD;
             reaction (RT-PCR), participants presenting any signs or symptoms as detected at&#xD;
             baseline following careful physical examination (e.g. cough, fever, headaches,&#xD;
             fatigue, dyspnea, myalgia, anosmia, dysgeusia, anorexia, sore throat, others) or&#xD;
             reporting any signs and symptoms for the 2 preceding weeks, or participants who have&#xD;
             been exposed to individuals with confirmed or suspected diagnosis of SARS-CoV-2 within&#xD;
             2 weeks prior to baseline. In addition, any other locally applicable standard&#xD;
             diagnostic criteria may also apply to rule out SARS-CoV-2 infection.&#xD;
&#xD;
        Note: Other protocol-defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Speziale</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Center Teodora</name>
      <address>
        <city>Ruse</city>
        <zip>7000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT Sv. Ivan Rilski EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aversi Clinic Ltd</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consilium Medulla-multiprofile clinic Ltd</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Grunwald</name>
      <address>
        <city>Poznan</city>
        <zip>60-369</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych S.C.</name>
      <address>
        <city>Poznań</city>
        <zip>60-773</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRI of Invalid Rehabilitation (EST Complex) of Vinnytsia M.I.Pyrogov NMU MOHU</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Clinic of Modern Rheumatology</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Georgia</country>
    <country>Poland</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arthritis</keyword>
  <keyword>Rheumatic Diseases</keyword>
  <keyword>Moderately active rheumatoid arthritis</keyword>
  <keyword>Severely active rheumatoid arthritis</keyword>
  <keyword>Joint Diseases</keyword>
  <keyword>Autoimmune Diseases</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <keyword>Musculoskeletal and connective tissue disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

